The effect of silymarin on liver enzymes
and antioxidant status in trauma patients
in the intensive care unit: a randomized double
blinded placebo-controlled clinical trial

Mirzaei, Ehsan; Sabetian, Golnar; Masjedi, Mansoor; Heidari, Reza; Mirjalili, Mahtabalsadat; Dehghanian, Amirreza; Vazin, Afsaneh

doi:10.5114/ceh.2021.107067

Cited by 17 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 1607 titles and abstracts were reviewed, and then 1595 studies were removed. Finally, 41 eligible studies were considered in this meta‐analysis after a full‐text review (Abbasirad et al, 2021; Ahmed et al, 2022; Anushiravani et al, 2019; Aryan et al, 2022; Bárcena et al, 2013; Darvishi‐Khezri et al, 2017; Di Pierro et al, 2013; Ebrahimpour Koujan et al, 2015; Elgarf et al, 2015; Fallah Huseini et al, 2005; Fallahzadeh et al, 2012; Firuzi et al, 2016; Fried et al, 2012; Gharagozloo et al, 2009; Gordon et al, 2006; Hajaghamohammadi et al, 2008; Hashemi et al, 2009; Heo et al, 2017; Huseini et al, 2004, 2006; Kheong et al, 2017; Luangchosiri et al, 2015; Lucena et al, 2002; Masoodi et al, 2013; Mirhashemi et al, 2022; Mirnezami et al, 2020; Mirzaei et al, 2021; Moayedi et al, 2013; Moezian et al, 2022; Mohaghegh et al, 2015; Momeni et al, 2015; Palasciano et al, 1994; Parés et al, 1998; Ramezani et al, 2008; Razzaq et al, 2011; Rendina et al, 2014; Salmi & Sarna, 1982; Simanek et al, 2001; Solhi et al, 2014; Taghvaei et al, 2013; Valentová et al, 2008).…”

Section: Resultsmentioning

confidence: 99%

“…These were published between 1982 and 2022. Thirty‐nine studies were parallel trials (Abbasirad et al, 2021; Ahmed et al, 2022; Anushiravani et al, 2019; Aryan et al, 2022; Bárcena et al, 2013; Di Pierro et al, 2013; Ebrahimpour Koujan et al, 2015; Elgarf et al, 2015; Fallah Huseini et al, 2005; Fallahzadeh et al, 2012; Firuzi et al, 2016; Fried et al, 2012; Gharagozloo et al, 2009; Hajaghamohammadi et al, 2008; Hashemi et al, 2009; Heo et al, 2017; Huseini et al, 2004, 2006; Kheong et al, 2017; Luangchosiri et al, 2015; Lucena et al, 2002; Masoodi et al, 2013; Mirhashemi et al, 2022; Mirnezami et al, 2020; Mirzaei et al, 2021; Moayedi et al, 2013; Moezian et al, 2022; Mohaghegh et al, 2015; Momeni et al, 2015; Palasciano et al, 1994; Parés et al, 1998; Ramezani et al, 2008; Razzaq et al, 2011; Rendina et al, 2014; Salmi & Sarna, 1982; Simanek et al, 2001; Solhi et al, 2014; Taghvaei et al, 2013; Valentová et al, 2008) and two were crossover studies (Darvishi‐Khezri et al, 2017; Gordon et al, 2006). The duration of the trials and sample sizes varied from 2 to 96 weeks and from 16 to 200 participants, respectively.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

Mohammadi,

Ashtary‐Larky,

Asbaghi

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

It is suggested that supplementation with silymarin (SIL) has beneficial impacts on kidney and liver functions. This systematic review and dose–response meta‐analysis assessed the impact of SIL administration on certain hepatic, renal, and oxidative stress markers. A systematic search was conducted in various databases to identify relevant trials published until January 2023. Randomized controlled trials (RCTs) that evaluated the effects of SIL on kidney and liver markers were included. A random‐effects model was used for the analysis and 41 RCTs were included. The pooled results indicated that SIL supplementation led to a significant reduction in serum levels of alkaline phosphatase, alanine transaminase, creatinine, and aspartate aminotransferase, along with a substantial elevation in serum glutathione in the SIL‐treated group compared to their untreated counterparts. In addition, there was a nonsignificant decrease in serum levels of gamma‐glutamyl transferase, malondialdehyde (MDA), total bilirubin, albumin (Alb), total antioxidant capacity, and blood urea nitrogen. Sub‐group analyses revealed a considerable decline in MDA and Alb serum values among SIL‐treated participants with liver disease in trials with a longer duration (≥12 weeks). These findings suggest that SIL may ameliorate certain liver markers with potential hepatoprotective effects, specifically with long‐term and high‐dose supplementation. However, its nephroprotective effects and impact on oxidative stress markers were not observed. Additional high‐quality RCTs with longer durations are required to determine the clinical efficacy of SIL supplementation on renal and oxidative stress markers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

Mohammadi,

Ashtary‐Larky,

Asbaghi

et al. 2024

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Some studies revealed that silymarin (140 mg, three times daily) could significantly lower the serum levels of AST, ALT, and alkaline phosphatase in trauma patients with increased levels of liver enzymes (Mirzaei et al, 2021 ). Another study recommended that the use of silymarin (420 mg per day) in non‐alcoholic hepatic steatosis patients could significantly reduce the AST and ALT levels in patients after six months (Abbasirad et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial

Aryan

Farahani

Chamanara

et al. 2022

Phytotherapy Research

View full text Add to dashboard Cite

Considering the outbreak pandemic of Coronavirus Disease 2019 (COVID‐19), the lack of effective therapeutic strategies for the management of this viral disease, and the increasing evidence on the antiviral potential of silymarin, this study aimed to investigate the effectiveness of silymarin nanomicelles on the symptom's resolution time, laboratory parameters, and liver enzymes in patients with COVID‐19. The participants were assigned to the nano‐silymarin ( n = 25) (receiving SinaLive soft gel, containing 70 mg silymarin as nanomicelles) or placebo groups ( n = 25) three times daily for two weeks. Patients' symptoms and laboratory findings were assessed at baseline and during the follow‐up period (one week and one month after the beginning of the treatment). No significant differences were observed between the two groups in terms of symptoms resolution time, laboratory parameters, and hospitalization duration ( p > 0.05). However, the alanine aminotransferase level decreased significantly in the treatment group, compared to the placebo group ( p < 0.001). Concomitant use of dexamethasone and remdesivir with silymarin might make the effects of silymarin on the improvement of patients' condition unclear. Further clinical trials are recommended with diverse dosages and larger sample sizes.

show abstract

“…The most important antioxidant mechanism of sylimarin is its ability to inhibit the enzymes involved in the production of ROS, preventing free radical formation [ 12 ]. At T0, the pattern of oxidant/antioxidant activity was characterized by high dROM values and low SHp values outside the physiological range reported for dogs, as previously reported for dogs living in shelters [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Antioxidant and Hepatoprotective Effect of a Nutritional Supplement with Silymarin Phytosome, Choline Chloride, l-Cystine, Artichoke, and Vitamin E in Dogs

et al. 2022

View full text Add to dashboard Cite

Phytotherapy has been promoted for the treatment of liver diseases in dogs. The interest in identifying the antioxidant/hepatoprotective potential of various plants is increasing. Every 10 days for 30 days, forty dogs were subjected to blood sampling and hepatic ultrasound assessment. Clinically healthy dogs (group A) and dogs with liver enzyme and ultrasound hepatic aspects and sizes outside the physiological range (group B) were divided into two subgroups. Every day for 30 days, one subgroup received Epacare pet + pasta® and the other received a placebo. Differences due to groups were observed in dROM, SHp, AST and LDH serum concentrations. The administration of Epacarepet + pasta® for 30 days had an influence on the serum concentration of dROMs, SHp, AST, ALT, ALP, LDH, and urea. The application of paired Student’s t-test showed a decrease in the longitudinal and transverse liver axis size. In conclusion, feed supplementation with Epacare pet + pasta® had a beneficial effect on the antioxidant status and liver enzymes in animals with liver enzymatic alterations and in healthy dogs.

show abstract

The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial

Cited by 17 publications

References 30 publications

Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

Evaluation of the efficacy of oral nano‐silymarin formulation in hospitalized patients with COVID‐19: A double‐blind placebo‐controlled clinical trial

Antioxidant and Hepatoprotective Effect of a Nutritional Supplement with Silymarin Phytosome, Choline Chloride, l-Cystine, Artichoke, and Vitamin E in Dogs

Contact Info

Product

Resources

About